Breast Cancer

BPA exposure accelerates ER+ breast cancer growth, impacting treatment efficacy and altering the pharmacist's role in therapy administration.

Hormonal contraceptives present a nuanced risk-benefit profile, slightly increasing breast and cervical cancer risk while significantly reducing ovarian and endometrial cancer rates.

Research reveals that higher BMI in women with cardiovascular disease significantly increases breast cancer risk, highlighting the need for targeted prevention strategies.

Obesity and high-fat diets enhance the aggressiveness of triple-negative breast cancer through exosome-mediated mechanisms, revealing new therapeutic targets.

Research reveals a link between estrogen plus progestin hormone therapy and increased breast cancer risk in young women, urging personalized treatment approaches.

Ribociclib plus endocrine therapy shows improved survival in HR+, HER2- breast cancer, but its cost-effectiveness raises concerns in the US market.

New research finds that adding carboplatin to paclitaxel and adjuvant chemotherapy shows no significant survival benefits in triple-negative breast cancer (TNBC).

Clairity Breast's FDA-approved AI platform revolutionizes breast cancer risk prediction, enhancing early detection and personalized prevention strategies.

Explore the complexities of managing toxicities in breast cancer treatments, including endocrine therapies, antibody drug conjugates, and immune checkpoint inhibitors.

APOBEC3 mutagenesis emerges as a key factor in breast cancer treatment resistance, offering new avenues for targeted therapies and predictive biomarkers.

In premenopausal women, denosumab significantly prevented bone loss and microarchitectural deterioration.

Combining olaparib with neoadjuvant chemotherapy enhances survival rates for early-stage gBRCAm triple-negative breast cancer, offering new hope for patients.

Abemaciclib and ribociclib have various risks and benefits in treating early breast cancer, highlighting the importance of patient-provider communication.

Pharmacists can educate patients on nonpharmacologic strategies that help improve survival outcomes.

Updates on April 30, 2025, introduce changes to treatment regimens, sequencing flexibility, febrile neutropenia risk assessments, and drug-specific safety and supportive care guidance.

Hyperglycemia is a common and significant adverse effect of PI3K and AKT inhibitors in hormone receptor-positive (HR+) breast cancer.

Study shows a significant decline in breast cancer mortality across multiple subtypes.

The combination yielded superior progression-free (PFS) survival compared with standard of care.

Breast cancer treatment is highly individualized and based on the stage, hormone receptor status, HER2 expression, and patient-specific factors.

Fatty acid metabolism plays a critical role in treatment responses.

Evolving breast cancer risk models and prevention methods are necessary to improve patient outcomes, according to Sagar Sardesai, MD.

Aromatase inhibitors were superior to tamoxifen in reducing risk of contralateral breast cancer.

The findings provide a deeper understanding of the mechanisms underlying breast cancer progression and treatment resistance.

Even when safe, oral supplement use may not be appropriate to use during cancer treatment or recovery.

Panelists discuss how when making antibody-drug conjugate (ADC) treatment decisions for patients with metastatic breast cancer (mBC), pharmacists primarily consider patient-specific factors such as biomarker status, prior therapies, disease burden, and comorbidities. ADCs are typically introduced after standard first-line treatments show inadequacy or in specific molecular subtypes that demonstrate strong responses to targeted therapy.

Panelists discuss how antibody-drug conjugates (ADCs) for breast cancer (BC) differ in their safety profiles, with trastuzumab deruxtecan (T-DXd) having notable interstitial lung disease risk, sacituzumab govitecan (SG) associated with neutropenia/diarrhea, and datopotamab deruxtecan (Dato-DXd) showing a relatively favorable safety profile but still requiring monitoring.

The authors’ findings show a greater decline in those treated with chemotherapy vs endocrine therapy.

New drugs and collaborative care may be key to overcoming trial closures, weak guidelines, and inefficiencies.

Sacituzumab govitecan improves outcomes but requires careful management of adverse effects.